Welcome to the SUM Breast Cancer Cell Line Gateway, your starting point for exploring the unique characteristics of each of the SUM breast cancer cell lines. Every cell line page provides detailed patient backgrounds, identified driving oncogenes, and access to our custom data mining applications.
We highly recommend using the Gene Query and KEGG Pathway Engine for in-depth biological investigations. To see these tools in action, please view our tutorial videos. Onward!
Here are the links that will take you to the Knowledge Base for each of the SUM breast cancer cell lines.
- SUM-44 ER+, HER2 negative cell line derived from a pleural effusion from a patient with lobuluar breast cancer. The cells have the CDH1 point mutation
- SUM-52 ER-/HER2 negative cell line. This is a luminal cell line was derived from a pleural effusion specimen. The primary breast cancer was ER+. The cells an amplification and overexpression of FGFR2
- SUM-102 ER-/HER2/EGFR+ cell line derived from a primary tumor specimen from a patient with extensive DCIS with microinvasion
- SUM-149 Derived from a primary tumor specimen from a patient with locally advanced inflammatory breast cancer. The cells were obtained following neo-adjuvant chemotherapy
- SUM-159 ER-/HER2- cell line derived from a primary tumor specimen that was classified as an anaplastic carcinoma. This is a highly mesenchymal cell line with an H-RAS mutation
- SUM-185 ER-/HER2- cell line derived from a pleural effusion specimen. The cells have an amplification and overexpression of FGFR3 and BCL2L1 and have a recurrent PIK3CA point mutation.
- SUM-190 ER-/HER2+ cell line derived from a primary tumor of a patient with an inflammatory breast cancer. These cells also have a recurrent PIK3CA point mutation in addition to the HER2 gene amplification.
- SUM-225 ER-/HER2+ cell line derived from a chest wall nodule from a patient who had surgery for an extensive DCIS.
- SUM-229 ER-/HER2-/EGFR+ cell line derived from a pleural effusion of a patient with aggressive basal breast cancer. These cells have a K-RAS point mutation
- SUM-1315 ER-/HER2/ cell line derived from the second transplant generation derived from a skin metastasis from a patient with highly aggressive and widely metastatic disease
Click here to get to the data mining apps for the SUM breast cancer cell lines.
How to acquire the SUM breast cancer cell lines.
Back to SLKBase Home
